Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 1st 3Qtrs Business Results
February 9, 2004
- Antihistamic Drugs Marketing Stiffer Competition (2)
February 9, 2004
- Approval for Levitra, Sandostatin LAR Recommended
February 9, 2004
- BUSINESS NEWS IN BRIEF
February 9, 2004
- Website News
February 9, 2004
- BULLETIN
February 9, 2004
- Gov't-managed Health Insurance Reports 1st Surplus in 10 Yrs
February 9, 2004
- Cultural Sensitivity Is Very Important: Mr Mazzo of AMO
February 9, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 9, 2004
- M-VAC Therapy Approved
February 9, 2004
- Anunal Business Results
February 9, 2004
- Approval of 15 New Drugs Notified
February 9, 2004
- Semi-anunal Business Results
February 9, 2004
- 30 NCEs Approved in January-November 2003: PFSB
February 9, 2004
- 3rd Qtr Business Results
February 9, 2004
- 70%-Multiple Rule to Be Used in Initial NHI Listing for Generics
February 9, 2004
- PRESS SEMINAR
February 9, 2004
- 5 Deaths by Interstitial Pneumonia Linked to Aventis' Arava
February 9, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
February 9, 2004
- Nat'l Hospitals, Sanatoriums to Fully Pay Drug Costs: Health Minister
February 9, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…